HOUSTON, Oct. 1, 2019 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
it has completed all patient treatments in the keloid scar
proof-of-concept trial.
Join our more than 200K fans here
to follow the Company: https://soly-investors.com
The study, conducted by Dr. Brenda
LaTowsky, Board Certified Dermatologist at Clear
Dermatology & Aesthetic Center in Scottsdale, AZ, was designed to
evaluate the safety and efficacy for all patients through a
12-week time point. The study will monitor and track the progress
of the results at both the 6-week and 12-week timepoints from
initial treatment in order to evaluate both the near-term and
continued longer-term effects.
Dr. Chris Capelli, President, CEO
and co-founder of Soliton, commented, "We eagerly anticipate the
follow-up visits with these patients. Demonstrating success in this
trial would lay a foundation for Soliton to pursue treatment for
many other fibrotic disorders."
Keloid and hypertrophic scars represent wound healing gone awry.
A typical example would be a post-surgical scar that grows beyond
its boundaries. Existing published research suggests that factors
relating to the wound-healing environment (including tension at the
boundary of the scar) can cause fibroblasts to become stuck in a
hyper-productive loop, unable to stop the production of collagen
that leads to the thickened, raised and dense structures often
associated with these fibrotic scars.
The American Osteopathic College of Dermatology estimates that
keloids affect around 10 percent of people,
whereas hypertrophic scars are more common. Keloid
scars are more prevalent among populations with darker
pigmentation. Hypertrophic scars affect men and women from any
racial group equally, although people between the ages of
10 and 30 years old are more likely to be affected.
Market Research Futures estimates the global market for keloid
and hypertrophic scars may reach $3.9
billion by 2023. There are few treatment options available
for fibrotic scars, which in addition to being disfiguring, can
also cause significant discomfort. Currently, the most common
treatment is the direct injection of steroids into the scar,
however this can require multiple injections and may not be a
permanent solution.
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal
methods. Soliton is investigating potential additional
capabilities of the RAP technology in preclinical testing,
including the potential to assist existing fat reduction technology
in the reduction of fat as well as improving the appearance of
cellulite by creating mechanical stress at the cellular level and
inducing significant collagen growth.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of the Soliton RAP
device to demonstrate safety and efficacy in the reduction of
keloid and hypertrophic scars, the ability for Soliton to receive
FDA clearance for these additional indications and the ability of
Soliton to pursue treatment of other fibrotic disorders. These
statements relate to future events, future expectations, plans and
prospects. Although Soliton believes that the expectations
reflected in such forward-looking statements are reasonable as of
the date made, expectations may prove to have been materially
different from the results expressed or implied by such
forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under the heading "Item 1A. Risk Factors" in the Form
10-K for year ended December 31, 2018
we filed with the SEC and updated from time to time in our Form
10-Q filings and in our other public filings with the SEC. Any
forward-looking statements contained in this release speak only as
of its date. Soliton undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
View original
content:http://www.prnewswire.com/news-releases/soliton-completes-keloid-poc-clinical-trial-treatments-300928340.html
SOURCE Soliton, Inc.